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Abstract
Background: Berberine is the major alkaloidal component of Rhizoma coptidis, and has multiple
pharmacological effects including inhibiting acetylcholinesterase, reducing cholesterol and glucose,
lowering mortality in patients with chronic congestive heart failure and anti-inflammation etc. Thus
berberine is a promising drug for diabetes, hyperlipemia, coronary artery disease and ischemic
stroke etc. The present study was carried out to investigate the effect of berberine chloride on the
spatial memory, inflammation factors interleukin-1 beta (IL-1beta) and inducible nitric oxide
synthase (iNOS) expression in the rat model of Alzheimer's disease (AD) which was established by
injecting Abeta (1–40) (5 microgram) into the rats hippocampuses bilaterally.
Results: The rats were given berberine chloride (50 mg/kg) by intragastric administration once
daily for 14 days. The spatial memory was assayed by Morris water maze test, IL-1beta and iNOS
in the hippocampus were assayed by immunohistochemistry and real time polymerase chain
reaction (PCR). Intragastric administration of berberine significantly ameliorated the spatial
memory impairment and increased the expression of IL-1beta, iNOS in the rat model of AD.
Conclusion: Berberine might be beneficial to AD by intragastric administration though it might
exaggerate the inflammation reaction.
Background
AD is the most prominent dementia in senile population
affecting approximately 5% of the over 65-year old popu-
lations, but the cause of AD remains largely unknown. In
the pathogenesis of AD, the inflammation mechanism is
seemed to play an important role [1]. The senile plaque is
the hallmark of AD. The core of the senile plaque is the
deposition of β-amyloid (Aβ) and the activated microglia
and astroglia are around the senile plaque. In these glias,
numerous inflammation factors including IL-1β, inter-
leukin -6(IL-6), tumor necrosis factor-α (TNF-α) and
iNOS etc, are overexpressed. These inflammation factors
have been seemed to be neurotoxic. At the same time,
some epidemiological studies demonstrated that long-
term use of nonsteroidal anti-inflammatory drugs
(NSAIDs) could prominently delay the onset of AD [2-5].
The current drugs for AD treatment including cholineste-
rase inhibitors (donepezil, rivastigmine and galan-
thamin) and N-methyl-D-aspartate (NMDA) receptor
antagonist (memantine) which were approved by Food
and Drug Administration of USA (FDA) are symptomatic
treatment, but these drugs usually can not delay the devel-
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opment of AD. Anti-inflammation drugs are expected to
delay AD, but most clinical research results of NSAIDs on
AD are negative [6]. Moreover some selective COX-2
inhibitors increased the occurrence of cardiovascular acci-
dents [7,8].
Berberine is an isoquinoline alkaloid with a long history
of medicinal usage in China. It exists in Hydrastis canaden-
sis (goldenseal), Cortex phellodendri (Huangbai) and Rhi-
zoma coptidis (Huanglian). These medicinal plants have
been widely used as traditional medicines for treating
diarrhea and gastrointestinal disorders for a long time in
China. Berberine, the major ingredient of these herbs, has
multiple pharmacological effects. It is a acetylcholineste-
rase inhibitor similar to Galanthamine[9], a drug treating
AD, and might be a low-molecular-weight neurotrophic
drug to neurodegeneration disorder such as AD by poten-
tiating the nerve growth factor (NGF)-induced differenti-
ation in neural cells [10]; berberine is a novel cholesterol-
lowering drug distinctly from statins by stabilizating the
low density lipoprotein receptor (LDLR) mRNA to
increase LDLR expression and inhibiting lipid synthe-
sis[11,12]. Berberine is also able to exert a glucose-lower-
ing effect by insulin independent manner [13],
stimulating insulin secretion and effectively sensitizing
insulin activity [14,15]. So berberine can play an impor-
tant role on metabolic syndrome. Berberine could
improve quality of life and decrease ventricular premature
complexes and mortality in patients with chronic conges-
tive heart failure [16]. Berberine has potential in the pre-
vention of atherosclerosis and restenosis [17,18].
Berberine can block transient outward potassium current
(IA) and delayed rectifier potassium current (IK) in a con-
centration-dependent manner in acutely isolated CA1
pyramidal neurons of rat hippocampus [19]. A recent
study demonstrated that mutations in voltage-gated
potassium channel KCNC3 caused adult-onset ataxia
[20], and potassium channels are regarded to play a key
role in neurodegeneration including AD [21]. So berber-
ine might be useful for the treatment of neurodegenera-
tion disorders including AD.
Except the above pharmacological effects, extracts
obtained from the roots of berberidaceae species have
been used in Eastern and Bulgarian folk medicines for the
treatment of rheumatic and other chronic inflammatory
disorders. Berberine suppressed a delayed type hypersen-
sitivity (DTH) reaction in a chronic inflammatory model
of adjuvant arthritis and diminished the antibody
response against sensitization red blood cell (SRBC) in
vitro [22]. In recent years, it was demonstrated that berber-
ine could inhibit the expression of some inflammation
factors. It might inhibit arachidonic acid metabolism in
rabbit platelets and endothelial cells [23]. Berberine could
decrease cyclooxygenase-2 (COX-2) expression by directly
inhibiting the activator protein-1(AP-1) binding and IL-
1β and TNF-α productions in HepG2 cells and cardiomy-
ocyte through nuclear factor-κB (NF-κB) signaling path-
way [24-27]. It could decrease IL-6 production in
esophageal cancer cells and inhibit expression of iNOS
mRNA in ethanol-induced gastric ulcer mice [28,29].
So berberine might be a very promising drug to treat the
cardiac disease, stroke, diabetes and hyperlipoidemia and
chronic inflammation diseases. So far, whether berberine
might be beneficial to AD by decreasing the inflammation
factors expression has not been studied. To test the
hypothesis that berberine might inhibit the inflammation
factors IL-1β and iNOS expression in the rat model of AD,
we used the rat model of AD established by injecting
Aβ(1–40)(5 µg) into the bilateral hippocampuses with
stereotaxic coordinates and gave the rats berberine chlo-
ride (50 mg/kg) intragastricly for 14 days. It was very sur-
prising that we found berberine chloride could
significantly ameliorate the spatial memory impairment
and increase these two factors expression.
Results
Effects of berberine chloride on the impairment of spatial 
memory
Rats were trained in the water maze for 7 days starting at
the eighth day after the injection of Aβ(1–40) (5 µg). Rats
were more efficient at finding the platform on successive
trails (Figure 1A). The main effect for each day was signif-
icant (P < 0.01). The main effect of berberine chloride was
also significant (P < 0.01). Two-way repeated measure
analysis of variance (two-way RM ANOVA) revealed a sig-
nificant increase in escape latency to find the platform in
the Aβ(1–40)-injected group as compared with the nor-
mal group (P < 0.01) and a significant decrease in escape
latency when berberine chloride (50 mg/kg) was intragas-
ticly administrated as compared with the Aβ(1–40) -
injected group(P < 0.01).
In the retention test (Figure 1B), the number of crossings
over a platform position was significantly decreased in the
Aβ(1–40)-injected group as compared with that in the
normal group (P < 0.01). The crossing number was recov-
ered by treatment with berberine chloride and the recov-
ery was significant (P < 0.01). All rats showed normal
swimming performance and constant increases in body
weight. Locomotor activity did not show difference
among groups.
Immunohistochemical evaluation of the effects of 
berberine chloride on the expression of IL-1β and iNOS
The effects of berberine chloride on the expression of IL-
1β and iNOS were investigated after the berberine chlo-
ride treatment (50 mg/kg) for 14 days by immunohisto-
chemistry. The injection of Aβ(1–40)(5  µg) in theBMC Neuroscience 2006, 7:78 http://www.biomedcentral.com/1471-2202/7/78
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hippocampus highly induced the increase of IL-1β and
iNOS immunostainings (P < 0.01), which were more sig-
nificantly increased in the berberine chloride-treated
rats(P < 0.01) (Figure 2, 3). The number of IL-1β-positive
cells increased from 22.7 ± 8.3 (normal group) to 58.8 ±
10.7 (Aβ(1–40) group) and 90.5 ± 12.2 (Aβ(1–40) + ber-
berine group) (Figure 2D), and the number of iNOS-pos-
itive cells also increased from 42.5 ± 10.2 (normal group)
to 103.0 ± 13.9 (Aβ(1–40)group) and 149.5 ± 11.9
(Aβ(1–40) + berberine group) (Figure 3D).
Evaluation of the effects of berberine chloride on the 
mRNA of IL-1β and iNOS by real time PCR
The effects of berberine chloride on the mRNA of IL-1β
and iNOS were investigated after berberine chloride (50
m/kg) treatment for 14 days by real time PCR. Injection of
Aβ(1–40) (5 µg) in the hippocampus highly increase the
mRNA of IL-1β and iNOS (P < 0.01), which were even
more significantly increased in the berberine chloride-
treated rats (P < 0.01). The relative copies of IL-1β mRNA
on internal control β-actin (arbitrary unit) in the Aβ(1–
40) group and Aβ(1–40) + berberine group were
increased from 4.3 ± 1.7 to 5.8 ± 2.1 and 7.3 ± 1.7, respec-
tively (Figure 4A), and the relative copies of iNOS mRNA
on internal control β-actin (arbitrary unit) in the above
two groups were increased from 20.7 ± 7.9 to 33.7 ± 17.4
and 67.5 ± 22.5, respectively (Figure 4B).
Discussion
In this study, we observed that berberine chloride (50 mg/
kg) could significantly decrease the escape latency and
increase the number of crossings over the platform posi-
tion in the rats model of AD assayed by Morris water maze
test, and could also increase both IL-1β and iNOS expres-
sion very significantly assayed by immunohistochemical
method. These results are not coincide with the previous
studies that berberine could inhibit the expression of
iNOS and IL-1β [26,29]. The difference between our
results and those of previous studies might be due to the
different administration mode of berberine and the effect
that berberine can increase non-specific immunity. Ber-
berine was intraperitoneally administrated or used in cells
culture model in the reported studies in contrast to the
intragastric administration in the present experiment. The
uptake rate of berberine by intragastric administration is
very low [30]. So the concentration of berberine in blood
or cell culture medium in the reported studies is higher
than the level in the present investigation. The different
level of berberine may cause different effects on the
immunity and inflammation factors' expression.
Berberine has been used by oral administration as an
unprescribed drug in China, and the safety and efficacy of
berberine by this administration mode have been gener-
ally accepted. Moreover, berberine (50 mg/kg -100 mg/
kg) by intragastric administration can significantly exert
cholesterol-lowering effect on rats [11]. So in this study,
we chosed the dose 50 mg/kg to study berberine's effect
on the expression of IL-1β and iNOS because this dose
and administration mode are more close to the clinical
practice than veno-injection or intraperitoneal adminis-
tration. We presume that the increase of inflammation
factors IL-1β and iNOS might be related to the rising of
microglia activation. In another two previous studies, ber-
berine was demonstrated to be able to activate macro-
phages and increase the phagcytosing function of
peritoneal macrophages (PMΦ) and the production of IL-
1 by PMΦ in mice [31,32]. It is indicated that berberine is
a potent macrophage activator and can increase non-spe-
cific immunity. Moreover it was demonstrated that ber-
berine could decrease the expression of PPARγ2 mRNA
and protein which was a negative regulator of inflamma-
tion[33,34]. Microglia and PMΦ are originated from the
peripheric mononuclear macrophage. So berberine might
be able to activate the microglia to phagocytize the exoge-
nous Aβ(1–40) which was injected into hippocampus. In
Effect of berberine chloride on the impairment of spatial  memory induced by Aβ(1–40) injection Figure 1
Effect of berberine chloride on the impairment of 
spatial memory induced by Aβ(1–40) injection. (A) 
Escape latencies per group of four trials tested in a morris 
water maze over 7 days. (B) The number of crossings over a 
position where a platform had been was measured for 120 s 
at seventh days after the last acquisition test. Values repre-
sent the means ± SD of 6 rats. * P < 0.01 when compared 
with the normal group. # P < 0.01 when compared with the 
Aβ(1–40) injection group.BMC Neuroscience 2006, 7:78 http://www.biomedcentral.com/1471-2202/7/78
Page 4 of 9
(page number not for citation purposes)
Immunohistochemistrical evaluation of the effect of berberine chloride on the expression of IL-1β Figure 2
Immunohistochemistrical evaluation of the effect of berberine chloride on the expression of IL-1β. (A) the 
expression of IL-1β(arrow) in the normal rat hippocampus.(B) the expression of IL-1β(arrow) around the injection point 
(arrowhead) in the Aβ(1–40) group. (C) the expression of IL-1β(arrow) around the injection point (arrowhead) in the Aβ(1–
40)+berberine group.(D) the table represents the number of IL-1β positive cells around the injection point in 400× fields. Val-
ues represent the means ± SD of 6 rats.*P < 0.01 when compared with the normal group. # P < 0.01 when compared with the 
Aβ(1–40) group.(A,B,C: 200×)BMC Neuroscience 2006, 7:78 http://www.biomedcentral.com/1471-2202/7/78
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Immunohistochemistrical evaluation of the effect of berberine chloride on the expression of iNOS Figure 3
Immunohistochemistrical evaluation of the effect of berberine chloride on the expression of iNOS. (A) the 
expression of iNOS(arrow) in the normal rat hippocampus. (B) the expression of iNOS(arrow) around the injection point 
(arrowhead) in the Aβ(1–40) group. (C) the expression iNOS (arrow) of around the injection point (arrowhead) in the Aβ(1–
40)+berberine group.(D) the table represents the number of iNOS positive cells around the injection point in 400× fields. Val-
ues represent the means ± SD of 6 rats. *P < 0.01 when compared with the normal group. # P < 0.01 when compared with the 
Aβ(1–40) group.(A,B,C: 200×)BMC Neuroscience 2006, 7:78 http://www.biomedcentral.com/1471-2202/7/78
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another our study, we had also demonstrated that berber-
ine was able to increase the microglia activation and sig-
nificantly decrease the expression PPARγ after the injection
of Aβ(1–40) into the hippocampus (data not shown). So
in this study, berberine should be able to increase the
inflammation factors expression including IL-1β and
iNOS by increasing microglia activation.
It seems that berberine might not be beneficial to AD
because it can increase the inflammation factors' expres-
sion and microglia activation. But inflammation factors
might also be beneficial to central nervous system (CNS).
It was reported that IL-1β might be crucial to the repair of
the CNS presumably through the induction of astrocyte
and microglia-macrophage-derived insulin-like growth
factor-1(IGF-1), and IL-1β--/- mice failed to remyelinate
properly which was correlated to the lack of IGF-1 produc-
tion by microglia-macrophages and astrocytes and to a
profound delay of precursors differentiating into mature
oligodendrocytes [35]. So berberine might ameliorate the
pathologies of AD through increasing the expression of IL-
1β. At the same time, a very recent study demonstrated
that genetic removal of iNOS in mice expressing mutated
amyloid precursor protein resulted in pathological hyper-
phosphorylation of mouse tau, its redistribution to the
somatodendritic compartment in cortical and hippocam-
pal neurons, and aggregate formation. Lack of iNOS in the
amyloid precursor protein Swedish mutant mouse would
increase the insoluble Aβ levels, neuronal degeneration,
caspase-3 activation and tau cleavage. This phenomenon
suggested that nitric oxide (NO) acted as a junction point
between Aβ, caspase activation, and tau aggregation, and
iNOS deletion could promote multiple pathologies in a
mouse model of AD [36]. So berberine might be able to
ameliorate the multiple pathologies of AD by increasing
iNOS expression. Moreover, berberine might be beneficial
to the senile plaque clearance by increasing microglia acti-
vation. A recent study demonstrated that bone marrow-
derived microglia played a critical role in restricting senile
plaque formation in AD, and therapeutic strategies aiming
to improve bone marrow-derived microglia recruitment
could potentially lead to a new powerful tool for the elim-
ination of toxic senile plaques [37]. Another recent study
also demonstrated that suppressing microglia activation
and reducing inflammation factors expression by minoc-
ycline could enhance senile plaque formation [38]. More-
over AD might be associated with the aging of microglia
for postnatal microglia, non-adult microglia has the abil-
ity to phagocytose Aβ fibrils[39]. The above studies indi-
cated that anti-inflammation drugs might not be
beneficial to AD, which is consistent with the vague effect
of this kind of drugs including NSAIDs on AD. So berber-
ine might be beneficial to AD by enhancing the bone bar-
row derived mononuclear macrophage to cross the blood-
brain barrier (BBB) and to be activated microglia which
has the ability to phagocytose Aβ fibrils, clear the senile
plaque and produce the more inflammation factors.
Conclusion
Berberine might be beneficial to AD by ameliorating spa-
tial memory impairment, improving inflammation fac-
tors expression, activating microglia and the senile plaque
clearance. But further investigation is needed in AD trans-
genic models and clinical research to demonstrate the effi-
cacy of berberine to AD.
Evaluation of the effects of berberine chloride on the mRNA  of IL-1β and iNOS by Real time PCR Figure 4
Evaluation of the effects of berberine chloride on the 
mRNA of IL-1β and iNOS by Real time PCR. (A)Real 
time PCR results of berberine chloride on the IL-1β mRNA 
indicate that IL-1β mRNA level was increased in the Aβ(1–
40) group and Aβ(1–40)+berberine group. The result repre-
sents at least three independent experiments, and β-actin 
was used as an internal control.(B) Real time PCR results of 
berberine chloride on the iNOS mRNA indicates that iNOS 
mRNA level was increased in the Aβ(1–40) group and Aβ(1–
40)+berberine group. The result represents at least three 
independent experiments, and β-actin was used as an internal 
control. Values represent the means ± SD of 6 rats. *P < 0.01 
when compared with the normal group. # P < 0.01 when 
compared with the Aβ(1–40) injection group.BMC Neuroscience 2006, 7:78 http://www.biomedcentral.com/1471-2202/7/78
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Methods
Animals and drug treatments
Adult male Sprague-Dawley rats (n = 18) (220–250 g,
experimental animal center of Sun Yet-Sen University)
were housed 6 per cage with free access to food and water,
and were kept in a constant environment (22 ± 2°C, 50 ±
5% humidity, 12-h light/dark cycle). The rats were ran-
domly divided into three groups, including the normal
group, the Aβ(1–40) group and Aβ(1–40) + berberine
group. Aβ(1–40) (Sigma, St. Louis, MO.USA) was dis-
solved in sterile distilled water at a concentration of 5 µg/
µL, and incubated at 37°C for 7 days to obtain the aggre-
gated form. Under anesthetization, peptides (1 µL = 5 µg)
were injected into the bilateral hippocampuses, with ster-
eotaxic coordinates from the bregma being, in mm, A -3,
L/R-2.0, and V 3.5. After analepsia, berberine chloride (50
mg/kg) (Sigma, St. Louis, MO. USA) was administered
intragastricly once daily for 14 days. All experimental ani-
mals were overseen and approved by the Animal Care and
Use Committee of Sun Yet-Sen University before and dur-
ing experiments.
Morris water maze test
White-colored water was poured into a circular pool
(diameter, 120 cm; height, 28 cm), and a white platform
(diameter, 8.3 cm) was placed 1.5 cm below the water
level in the middle of a fixed quadrant. The water temper-
ature was adjusted to 25 ± 1°C. Memory-acquisition trials
(training) were performed four times daily for 7 days to
reach a steady state of escape latency. At 1 h after intragas-
tric administration of berberine chloride, the rats were
allowed to swim freely for 120 s and were left for an addi-
tional 30 s on the platform. The intertribal interval during
four trials was 75 min. Start positions set at each limit
between quadrants, were randomly selected for each ani-
mal. Rats failing to find the platform were placed on the
platform manually. Memory-retention tests were per-
formed at the seventh day after the last training session.
The platform was removed, and each rat was allowed a
free 120 s swim. The number of crossings over a point
where the platform had been was counted by replay using
a video recorder. Data are presented as mean ± SD.
Immunohistochemistry
Animals were perfused through the heart under deep
anaesthesia (chloral hydrate 0.35 mL/100 g) with 100 mL
of phosphate buffer saline (PBS) containing 10 U/mL
heparin followed by 150–200 mL of 4% paraformalde-
hyde in PBS, PH 7.4. Brains were removed and then
immersed in PBS containing sucrose, PH 7.4, first in 20%
sucrose for 24 h and then in 30% sucrose until sunk (2–5
days). 8 µm sections were cut on a cryostat and mounted
in polylysine -coated slices. The number of IL-1β and
iNOS positive cells around the point of injection were
analyzed immunohistochemically using an antibody
against IL-1β (sc-7784, dilution 1:50, Santa Cruz Biotech-
nology Inc., USA) and anibody against iNOS (SC-651,
dilution 1:50, Santa Cruz Biotechnology, Inc.USA.). For
the visualization under light microscope, incubation with
biotinylated rabbit/mouse anti-rat IgG (Dako Cytomation
Inc., USA) and the immunoreaction was visualized using
diaminobenzidine. Counting of IL-1β and iNOS -express-
ing cells was done by an observer blind to the treatment
status of the rats based on the visibility of a cell soma in 8
µm-thick coronal sections in 400 × fields by Olysia Biore-
port software (Olympus company, Japan). Four slides
around the injection point were evaluated per animal.
Data are presented as mean ± SD.
Real time PCR
Expressions of genes were further confirmed by real time
PCR. Primers were designed and synthesized by Takara
biotechnology Co., Ltd (Dalian, China). Total RNA was
isolated from hippocampus tissues using RNAiso reagent
(Takara biotechnology Co., Ltd, Dalian, China). First-
strand cDNA was synthesized from 0.5 µg of total cellular
RNA with randoms 6 mers with the ExScript™ RT Reagents
Kit (Takara biotechnology Co., Ltd, Dalian, China). After
incubation for 15 mins at 42°C, the RT mixture was incu-
bated at 95°C for 2 min to inactivate the reverse tran-
scriptase. Real time PCR cycles were carried out for
amplification of IL-1β, iNOS and β-actin cDNA using a
thermal cycler (MJ Research company, DFC-3200, USA).
The primers sequences for IL-1β were 5'- GCT GTG GCA
GCT ACC TAT GTC TTG -3' (sense) and 5'- AGG TCG TCA
TCA TCC CAC GAG -3' (antisense). The primer sequences
for iNOS were 5'- CTC ACT GTG GCT GTG GTC ACC TA
-3' (sense) and 5'- GGG TCT TCG GGC TTC AGG TTA -3'
(antisense). The primer sequences for β-actin were 5'- TGA
CAG G TG CAG AAG GAG A -3'(sense) and 5'- TAG AGC
CAC CAA TCC ACA CA-3'(antisense). Real time PCR was
then carried out using 2 µL cDNA in a final reaction vol-
ume 20 µL using SYBR Premix Ex Taq™ (Takara biotech-
nology Co., Ltd, Dalian, China). The PCR cycling program
was set for 1 cycle of pre-denaturation at 95°C for 10 s,
and then 39 cycles at 95°C for 5 s, 60°C for 20 s, 81°C
plate reading for 3 s, melting curve from 55°C to 95°C
read every 0.2°C hold for 1 s between reads. The relative
copies of IL-1β mRNA and iNOS mRNA on the internal
control β-actin are arbitrary units.
Statistical analysis
All of the data were expressed as mean ± SD and the anal-
ysis was carried out using the one way analysis of vari-
ance(ANOVA) or two-way RM ANOVA. Values of P < 0.05
were considered statistically significant.
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